Thrombus - 2014

Safety and efficacy of enoxaparin for thromboprophylaxis in obese patients
Rebecca Bushby
pp 1-5
Obesity is increasing in prevalence, with England and the rest of the UK reporting some of the highest rates of obesity in the Western world. The prevalence of obesity in English men has risen from 13% in 1993 to 24% in 2011; the prevalence in English women followed a similar pattern, rising from 16% in 1993 to 26% in 2011.

Comment: Complexities of cancer-associated venous thrombosis
Peter Rose
pp 2-2
The 7th International Conference on Thrombosis and Hemostasis Issues in Cancer was recently held in Bergamo, Italy. It is difficult to envisage a more splendid venue for a conference, set in the old walled city. The meeting itself was worthy of similar accolade and is now a biennial event, something for the diary for 2016.

Is resistance to antiplatelet therapy real?
Marie Lordkipanidzé
pp 6-8
Antiplatelet agents are an essential part of therapy, both in treatment and prevention of acute ischaemic events. Despite the overwhelming evidence in support of the efficacy of aspirin and P2Y₁₂ adenosine diphospate receptor inhibitors, such as clopidogrel, prasugrel and ticagrelor, in patients with cardiovascular diseases, there is ongoing debate on the issue of possible resistance to antiplatelet drugs.

Different models for delivering anticoagulation in primary care: is the only way Essex?
Andrew Hughes
pp 9-11
It is estimated that there are approximately 800,000 individuals being treated with an oral anticoagulant in England. However, this does not represent the total number of people who should be anticoagulated. Data from 2,108 general practices in England, which have used the Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation tool from NHS Improving Quality, show that only 56% of patients with atrial fibrillation with a CHADS₂ score of two or more are on an oral anticoagulant.

Post-nephrectomy DVT in a patient with idiopathic thrombocytopenic purpura
Sarah Bond
pp 12-13
Mr MF, aged 66, has anti-neutrophil cytoplasmic antibody-positive systemic vasculitis, which was diagnosed in 1995, along with lung haemorrhage (treated with methylprednisolone and cyclophosphamide, switching to azathioprine and prednisolone) and thrombocytopenia, which has been noted since the diagnosis of vasculitis. He had a deep vein thrombosis in 1996 with a subsequent diagnosis of a positive lupus anticoagulant.

FAQs: How do you decide which oral direct inhibitor to prescribe?
Nicola Korn
pp 14-15
The benefit of anticoagulants for stroke reduction in atrial fibrillation (AF) is well established. Until recently, the coumarins (for example, warfarin) were the only choice in oral anticoagulation. However, three oral direct inhibitors, the thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban and rivaroxaban, are now licensed and approved by the National Institute for Health and Care Excellence for use in stroke prevention in AF, and have shown at least equal efficacy and a more favourable bleeding risk profile compared with warfarin.

Spring 2014, Volume 18 Number 1

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print) ISSN 2045-7855 (Online)